The predicate study isn't the waiver study.

A test clears through a 510(k) using comparison and reproducibility studies run by trained laboratory staff, under controlled conditions, against a predicate. Later, the sponsor wants the test CLIA-waived — usable at the point of care, outside a certified lab — and the assumption is that the clearance data already proves the device works. FDA built a pathway that lets both decisions travel in one submission. It did not build a pathway where one study stands in for both.

What the dual pathway actually is

42 U.S.C. § 263a(d)(3) sets the statutory bar for a waived test: FDA approval for home use, or a method simple enough that it carries an insignificant risk of an erroneous result. Historically a sponsor cleared the device first and filed a separate CLIA Waiver by Application afterward. The Dual 510(k) and CLIA Waiver by Application pathway, created under MDUFA III in 2012 and finalized in its current guidance form in February 2020, lets a sponsor file one package covering both — reviewed together, decided together. FDA’s own guidance calls it optional, and in many cases the least burdensome route to the two outcomes at once.

The catch is the study, not the form

The dual pathway’s own guidance is explicit about what has to change in the protocol, not just the cover letter: the comparison and reproducibility testing has to use typical intended users with limited training, running the test in the kind of waived setting and with the kind of sample a point-of-care or lay user would actually encounter — not the trained-operator bench a standard 510(k) analytical study is built around. That choice gets made once, in the protocol a sponsor brings to a Pre-Submission before the pivotal study runs. A 510(k) study already completed with trained lab staff does not retroactively become a waiver study because the device later clears.

A clearance study proves a device works in the hands that ran it. A waiver has to prove the device works in the hands that will actually use it — and those can be two different studies entirely.

Two records, even after both land

Clearance and waived status don’t merge into one public entry once both are granted. The 510(k) database carries the clearance. Whether that same test also holds waived status lives in FDA’s separate CLIA Database and its Currently Waived Analytes list, updated on its own monthly schedule. Checking whether a competitor’s test cleared answers one question. Checking whether it’s also waived is a second lookup, in a second database, that a 510(k)-only watch never runs.

The method

A sponsor planning a dual submission raises the study design with FDA at the Pre-Submission stage, before locking a protocol built around trained operators in a controlled setting. The intended users and the test site belong to the waived population from the first draft, not as a patch applied after a 510(k) study already ran its course. This is regulatory intelligence about how the pathway and its evidence requirements are structured, never regulatory advice about whether a specific device’s existing data would support a waiver — that determination belongs with the sponsor’s own regulatory team, reading the actual protocol.